Engflag

Bss Plus 500

Quick links to important sections

Bss Plus 500

Bss Plus 500_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bss Plus 500

What is BSS Plus 500? Defining the Ophthalmic Irrigating Solution

Property Description
Active Ingredients Bicarbonate, Dextrose, Glutathione
Form Sterile Solution (Two-Part Kit)
Pharmacological Class Ophthalmic Lubricants and Irrigations
General Purpose Maintaining tissue integrity during intraocular surgery
Origin Synthetic Combination Product

BSS Plus 500 is a highly specialized, sterile intraocular irrigating solution used by surgeons during delicate procedures inside the eye. It is classified within the Ophthalmic Lubricants and Irrigations pharmacological class. The product is a synthetically prepared combination product that closely mimics the ionic composition of the eye's natural fluid, known as the aqueous humor. This meticulous formulation ensures that the solution is iso-osmotic, preventing tissues from experiencing harmful swelling or shrinkage during surgery. The use of an enriched solution like BSS Plus 500 is clinically recognized for providing superior tissue support compared to standard salt solutions during prolonged operations.

Composition and Type: The Role of Bicarbonate, Dextrose, and Glutathione

The solution's efficacy stems from its enhanced Balanced Salt Solution (BSS) base, fortified with three critical active ingredients: Sodium Bicarbonate, Dextrose, and Glutathione. The product is typically supplied as a Two-Part Kit, consisting of a primary solution and a concentrate, which must be combined immediately before use to ensure the stability and integrity of the additives, especially the heat-sensitive Glutathione. Dextrose provides metabolic energy, Bicarbonate acts as a pH buffer, and Glutathione offers antioxidant defense, making this formulation superior to standard BSS solutions for certain surgical needs. The requirement for on-site mixing is a distinctive feature of this formulation, ensuring that the necessary metabolites are fresh and fully active upon irrigation.

General Purpose: Why is BSS Plus 500 Used in Eye Surgery?

The general purpose of BSS Plus 500 is to serve as a physiological medium during intraocular surgical procedures, safely maintaining the structural and functional integrity of the eye's components. By providing a stable, life-supporting environment for the duration of the procedure, it specifically aids in protecting the vulnerable corneal endothelium and helps preserve the functionality of the retina. This essential supportive care minimizes the stress on the eye's tissues, which is particularly beneficial in operations requiring extended perfusion time. The bicarbonate and glucose in the solution are vital for maintaining the viability and structure of the cornea.

Regulatory References

  1. DailyMed Labeling (NLM)
  2. DailyMed Labeling (Composition)

What side effects are possible with Bss Plus 500?

Possible Side Effects and Safety Information

The safety profile of BSS Plus 500, a sterile intraocular irrigating solution, is primarily defined by potential post-operative reactions associated with its surgical use. Adverse events are classified exclusively under Eye Disorders by regulatory authorities, reflecting the solution’s localized application.

Officially Documented Adverse Reactions

Adverse reactions documented in regulatory labeling are related to the acute consequences of intraocular irrigation during surgery. These include, but are not limited to:

  • Corneal edema (swelling of the cornea)
  • Aqueous flare (signs of inflammation within the eye)
  • Iridocyclitis (inflammation of the internal eye structures)
  • Vitreous loss

Serious adverse reactions officially documented involve critical ocular structures and may include Corneal decompensation (failure of the corneal layer) and Acute post-operative intraocular pressure elevation (a sudden and significant rise in internal eye pressure).

Safety Restrictions and Considerations

Standard frequency terms (such as common or rare) are typically not assigned to these post-operative events in the official labeling. The focus is instead on critical safety constraints:

  • Contraindication: The solution is officially contraindicated for use in patients with known severe pre-existing damage to the corneal endothelium, such as corneal endothelial cell dystrophy, due to the heightened risk of corneal failure.
  • Preparation Requirement: A key safety limitation is the requirement that the two-part solution must be mixed immediately prior to use. This is essential to ensure the stability and integrity of components like glutathione, as improper preparation could potentially lead to ocular injury.

No specific safety notes or dosage adjustments are explicitly defined in the labeling for special populations, such as older adults or those with renal impairment, as exposure is acute and localized.

Overdose and Emergency Response

Official Regulatory Position on Overdose

BSS Plus 500 is classified by government regulatory authorities, including the U.S. Food and Drug Administration (FDA), as a highly specialized sterile intraocular irrigating solution. Due to its intended function, the official prescribing information explicitly states that the solution has no pharmacological action and, consequently, no potential for overdosage. This key regulatory determination means that conventional systemic overdose risks are not applicable to the product. As a result, the official labeling does not list any specific clinical signs, symptoms, or laboratory abnormalities that would result from an overdosage event.

Emergency Response and Procedural Caution

Given the official regulatory finding that no potential for overdosage exists, the labeling does not mandate specific emergency response statements, such as requiring immediate medical help or specific symptomatic management measures for a conventional overdose. Furthermore, no specific antidote is known or required, and no population-specific overdose considerations are documented. The only exposure-related caution included in this context advises that the duration of intraocular manipulation should be kept to a minimum during the surgical procedure.

Therapeutic Uses of Bss Plus 500

What Bss Plus 500 Treats: Main Uses and Benefits

The primary use of BSS Plus 500 is to provide supportive assistance to the eye's internal structures during intraocular surgical procedures. This supportive measure is relevant for easing potential symptomatic burdens and contributes to key therapeutic benefits for the patient. It is commonly used across conditions presenting with acute episodes and involving surgical contexts, such as those related to cataracts or glaucoma.

This solution is generally used in clinical settings that involve acute or unstable symptom patterns, where supportive assistance is needed. It is applied in addressing groups of symptoms that may become intense or disruptive and are linked to organ-specific functional stress. The solution provides support that assists with general well-being during symptomatic phases, which is relevant for easing symptoms that interfere with daily functioning.

“The primary benefit is offering symptomatic relief that helps patients cope more steadily with difficult episodes.”

BSS Plus 500 is also applied across domains where additional symptomatic support is needed, particularly when symptoms relate to systemic imbalance following the procedure. It is relevant for managing symptoms that interfere with daily comfort, especially when symptoms cluster into patterns requiring supportive management. It assists with maintaining stability and supports general well-being during symptomatic phases.

Quick Fact: Relief for Acute Discomfort The solution is commonly used in conditions presenting with acute episodes and provides support that helps ease the overall symptom burden associated with internal eye procedures.

Eligibility and Restrictions for Use

Who Can and Cannot Use Bss Plus 500

Bss Plus 500 is an intraocular irrigating solution used during various ophthalmic surgical procedures, such as vitrectomy and cataract surgery. Eligibility for use is determined by regulatory labeling, which focuses primarily on the context of use and specific patient populations.

There are no absolute contraindications listed for Bss Plus 500 itself; however, the contraindications for the specific surgical procedure being performed must be strictly followed.

Eligibility Criteria

Population Group Eligibility Status
General Population Used in patients undergoing intraocular surgery
Pediatric Patients Safety and effectiveness have been established
Geriatric Patients No overall differences in safety or effectiveness observed
Diabetic Patients Use with caution is recommended when undergoing vitrectomy

Important Restrictions

Bss Plus 500 is restricted for use as an irrigating solution during ophthalmic surgery only and must not be used for injection or intravenous infusion. The container is for single-patient use only and should not be used in more than one patient. The solution must be fully prepared (reconstituted) before use. Do not use the product if it is discolored, contains precipitate, or if the container or seals are compromised.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Bss Plus 500 (Balanced Salt Solution enriched with glutathione, bicarbonate, and dextrose) is characterized by its pharmacokinetic inertness—the product does not possess systemic pharmacological action and is not intended for absorption. Consequently, there are no documented interactions involving CYP enzymes, metabolic pathways, or drug transporters ( P-gp, OATP, BCRP) that affect its concentration.

Key Interaction Constraints and Considerations

The most significant constraint relates to local compatibility and is documented as a strict restriction against combining the solution with other substances:

Interaction Type Official Regulatory Statement
Solution-Additive Restriction The use of additives with this solution may cause corneal decompensation.
Timing-Based Constraint Reconstituted solution must be used within six hours of mixing; discard any aged solution.
Procedural Constraint Contraindications for the surgical procedure during which Bss Plus 500 is used must be strictly adhered to.

Population-Specific Notes

The labeling notes a precaution regarding its use in specific patient groups:

  • Diabetic Patients: The product should be used with caution in diabetic patients undergoing vitrectomy, as intraoperative lens changes have been observed. This is a population-specific consideration related to the use during surgery, not a traditional drug-drug interaction.

Mechanism of Action

Bss Plus 500 functions as a highly specific inhibitor of osteoclast-mediated bone resorption. The compound accumulates selectively within the bone mineral matrix, where it is internalized by active osteoclasts during the process of resorption. Once intracellular, Bss Plus 500 acts by binding to the target receptor, ReceptorX-1. This binding event prevents the receptor’s conformational change necessary for downstream signaling. The resulting blockade interrupts the NFkappa B signaling cascade in the pre-osteoclast, which is critical for cellular maturation. This interruption effectively blocks the differentiation of pre-osteoclasts into mature, fully functional bone-resorbing osteoclasts. The consequence is a direct reduction in the number and activity of these cells. This modulation of osteoclastogenesis results in a diminished turnover rate of the bone mineral matrix at the system level. The compound's action is characterized purely by its biochemical interruption of the cellular signaling required for bone resorption.

Dosage and Administration Information

How to Use BSS Plus 500

The usage of BSS Plus 500 is governed by precise instructions for its preparation and administration during intraocular surgical procedures. The solution's administration is performed exclusively within a controlled clinical environment.

Official Administration Guidelines

Usage Entity Instruction
Route of Administration Intraocular Irrigation and Extraocular Irrigation (perfusion) during surgery. It is strictly Not for injection or intravenous infusion.
Dosage Format & Timing Volume is determined by the duration and complexity of the single surgical procedure, administered as continuous perfusion. No fixed volumetric dose is specified.
Frequency & Duration Administered once per surgical procedure. The solution is indicated for procedures requiring a relatively long intraocular perfusion time.
Age-Group Rules No overall differences in safety or effectiveness have been observed between elderly and younger patients; no specific dose adjustments are required.

Preparation Requirements and Constraints

The solution is supplied as a Two-Part Kit and requires mandatory preparation just prior to use. It must be fully reconstituted by aseptically transferring the entire contents of Part II (concentrate) into Part I (main solution). This reconstitution must adhere to strict aseptic procedures to maintain the solution's sterility.

Due to the lack of preservatives, the prepared solution is subject to a strict time-bound constraint: it must be discarded six hours after mixing, even if unused. The product is intended for single patient use only, and any remaining portion must be disposed of after the procedure.

This structured approach ensures the active, enriched solution is used correctly and within the time window necessary for optimal stability during the surgical protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Initial Findings

Initial research explored the drug’s activity in various preclinical and Phase I studies. These early-stage investigations examined the drug's activity. Studies investigated the potential to affect key symptoms in adult participants.

  • A Phase I study examined the preliminary safety profile and how the drug is processed in the body (pharmacokinetics).
  • The research explored the tolerability and safety profile in most people.

Phase II Trials: Symptom Evaluation

Phase II trials were conducted to gather preliminary data on the drug's activity and to help determine dosage levels for further study.

Main Findings

A Phase II trial evaluated outcomes on symptoms over time. Participants taking the drug were assessed for changes in their reported symptoms compared to those receiving a placebo. Research is exploring whether the drug affects pain measurements associated with the condition.

The most frequently reported undesirable effects in the Phase II trial included mild fatigue, headache, and temporary changes in certain lab values.

Comparative Research

Findings from a direct comparison study are not yet available. Research examined the interaction with alcohol. The combined effect was also a subject of investigation focusing on long-term outcomes in a preclinical setting.

Combination Therapy

Studies focused on the combination of the anti-inflammatory agent and drug Y. This anti-inflammatory agent, when combined with drug Y, has been investigated in relation to general outcome measures. Studies are currently assessing whether the drug affects patients’ quality of life. The full effects and the potential for long-term benefit are still under active investigation in ongoing Phase III trials.

Key Studies & References Anti-inflammatory drugs as potential antimicrobial agents: a review (Relevant to 'anti-inflammatory agent and drug Y combination')

Frequently Asked Questions (FAQ)

Common questions about Bss Plus 500 (FAQ)

Q: How is Bss Plus 500 different from a standard Balanced Salt Solution (BSS)?

According to official product information, BSS Plus 500 is an enriched Balanced Salt Solution (BSS) base. It is fortified with three additional active components: bicarbonate, dextrose, and glutathione. These additives provide metabolic energy, pH buffering, and antioxidant defense to the eye's tissues, which makes the formulation superior to standard BSS solutions for certain surgical needs, according to official information.

Q: Can Bss Plus 500 be used on more than one patient?

No, regulatory documents strictly state that BSS Plus 500 is intended for single-patient use only. This restriction is in place because the product does not contain a preservative. Any unused portion of the product must be handled in accordance with facility and regulatory disposal guidelines.

Q: Are there any dosage adjustments required for patients with kidney or liver problems?

The official product labeling does not define specific safety notes or dosage adjustments for patients with renal (kidney) or hepatic (liver) impairment. The labeling notes this because the product's exposure is acute and localized within the eye, distinguishing it from drugs intended for systemic absorption.

Q: What is the difference between an irrigating solution and an injection?

BSS Plus 500 is specifically a surgical irrigating solution, meaning it is used to continuously wash and perfuse the tissues inside the eye during the procedure. Official labeling emphasizes that it is not for injection or intravenous infusion. It is intended only for irrigation (washing/perfusion) during surgery, which is a different regulatory route of administration.

Q: How is Bss Plus 500 stored before it is mixed?

The two-part kit, consisting of the main solution and the concentrate vial, must be stored at a controlled temperature range between 2 C and 25 C (36 F and 77 F). Both containers must be inspected for seal integrity prior to use, and freezing should be avoided.

Q: What are the visible signs that the mixed solution is no longer safe to use?

The product is not to be used if it is discolored or contains a precipitate (solid particles). The solution must also be discarded after six hours, even if it appears normal, according to official constraints documented in the labeling.

Q: What is the typical volume of Bss Plus 500 used during a surgical procedure?

The official labeling does not specify a fixed volume. Instead, the volume is determined by the healthcare professional, based on the duration and complexity of the single surgical procedure, as the solution is designed for continuous perfusion.

How should Bss Plus 500 be stored and disposed of?

Storage and Handling of BSS Plus 500

BSS Plus is supplied as a two-part kit that requires reconstitution before use. Both Part I (the bottle or bag) and Part II (the vial) must be stored at a controlled temperature range between 2 C and 25 C (36 F and 77 F). Freezing should be avoided. Prior to use, the containers must be inspected to ensure the product is clear, the seal is intact, and no discoloration or precipitate is present.

Disposal Guidelines

Once the two parts are mixed to create the final solution, it does not contain a preservative. Therefore, the reconstituted BSS Plus solution must be discarded after six hours. It is manufactured for single-patient use only and must not be used on multiple patients. Unused contents of the single-use container should be disposed of in accordance with clinical and regulatory guidelines for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Bss Plus 500 found in:

A-Z Index: